{"transactions":[{"id":4635178,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":30801,"kind":"person","name":"Harlow John B. Jr.","position":1,"cik":"0002095554","reported_name":"Harlow John B. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T00:27:13.000Z","date":"2026-09-29","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on September 29, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":800000,"derivative":{"exercise_price":3.14,"expiration_date":"2036-09-29","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001193125-26-410719","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526410719/ownership.xml","form_type":"4"}},{"id":4635177,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":30801,"kind":"person","name":"Harlow John B. Jr.","position":1,"cik":"0002095554","reported_name":"Harlow John B. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2026-10-02T00:27:13.000Z","date":"2026-09-29","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001193125-26-410719","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526410719/ownership.xml","form_type":"4"}},{"id":712501,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":31399,"kind":"person","name":"Hamilton Thomas Edward","position":1,"cik":"0001769848","reported_name":"Hamilton Thomas Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T20:05:03.000Z","date":"2026-07-06","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":3.3378,"value":166890.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.33 to $3.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":714798,"source":{"system":"sec-edgar","filing":"0001193125-26-298523","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526298523/ownership.xml","form_type":"4"}},{"id":770573,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-21T00:02:48.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":55150,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Through Deerfield Management Company, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on May 19, 2026 and is scheduled to vest on the earlier of May 19, 2027 and the date of the Issuer's next annual meeting of stockholders, in each case, subject to Jonathan S. Leff 's continued service on the board of directors of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). James E. Flynn is the sole member of the general partner of Deerfield Management Company, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":55150,"derivative":{"exercise_price":3.33,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":55150},"source":{"system":"sec-edgar","filing":"0001193805-26-000669","document":"e665501_4-larimar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380526000669/e665501_4-larimar.xml","form_type":"4"}},{"id":769738,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45622,"kind":"person","name":"LEFF JONATHAN S","position":1,"cik":"0001215242","reported_name":"LEFF JONATHAN S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T22:03:57.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":55150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."}],"balance_after":55150,"derivative":{"exercise_price":3.33,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":55150},"source":{"system":"sec-edgar","filing":"0001193125-26-232933","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1215242/000119312526232933/ownership.xml","form_type":"4"}},{"id":769735,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T20:30:21.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":55150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":55150,"derivative":{"exercise_price":3.33,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":55150},"source":{"system":"sec-edgar","filing":"0001193125-26-232705","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000119312526232705/ownership.xml","form_type":"4"}},{"id":769906,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T20:28:05.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":55150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":55150,"derivative":{"exercise_price":3.33,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":55150},"source":{"system":"sec-edgar","filing":"0001193125-26-232667","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000119312526232667/ownership.xml","form_type":"4"}},{"id":769768,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T20:24:58.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":55150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":55150,"derivative":{"exercise_price":3.33,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":55150},"source":{"system":"sec-edgar","filing":"0001193125-26-232657","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000119312526232657/ownership.xml","form_type":"4"}},{"id":769679,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":31399,"kind":"person","name":"Hamilton Thomas Edward","position":1,"cik":"0001769848","reported_name":"Hamilton Thomas Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T20:21:39.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":55150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":55150,"derivative":{"exercise_price":3.33,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":55150},"source":{"system":"sec-edgar","filing":"0001193125-26-232644","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526232644/ownership.xml","form_type":"4"}},{"id":875272,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29898,"kind":"person","name":"Deerfield Mgmt L.P.","position":6,"cik":"0001010823","reported_name":"Deerfield Mgmt L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":7,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":8,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":9,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29897,"kind":"person","name":"DEERFIELD PARTNERS, L.P.","position":10,"cik":"0001301041","reported_name":"DEERFIELD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2026-03-03T00:46:04.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":2000000,"price":5,"value":10000000.0,"ownership":{"direct":false,"nature":"Through Deerfield Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. (\"Deerfield Partners\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":6207982,"source":{"system":"sec-edgar","filing":"0001193805-26-000205","document":"e665206_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380526000205/e665206_4-larimar.xml","form_type":"4"}},{"id":875271,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29898,"kind":"person","name":"Deerfield Mgmt L.P.","position":6,"cik":"0001010823","reported_name":"Deerfield Mgmt L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":7,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":8,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":9,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29897,"kind":"person","name":"DEERFIELD PARTNERS, L.P.","position":10,"cik":"0001301041","reported_name":"DEERFIELD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2026-03-03T00:46:04.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":831978,"price":5,"value":4159890.0,"ownership":{"direct":false,"nature":"Through Deerfield Healthcare Innovations Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. (\"Deerfield Partners\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":8153107,"source":{"system":"sec-edgar","filing":"0001193805-26-000205","document":"e665206_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380526000205/e665206_4-larimar.xml","form_type":"4"}},{"id":875270,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29898,"kind":"person","name":"Deerfield Mgmt L.P.","position":6,"cik":"0001010823","reported_name":"Deerfield Mgmt L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":7,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":8,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":9,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29897,"kind":"person","name":"DEERFIELD PARTNERS, L.P.","position":10,"cik":"0001301041","reported_name":"DEERFIELD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2026-03-03T00:46:04.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":1084012,"price":5,"value":5420060.0,"ownership":{"direct":false,"nature":"Through Deerfield Private Design Fund IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. (\"Deerfield Partners\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":10622957,"source":{"system":"sec-edgar","filing":"0001193805-26-000205","document":"e665206_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380526000205/e665206_4-larimar.xml","form_type":"4"}},{"id":875269,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29898,"kind":"person","name":"Deerfield Mgmt L.P.","position":6,"cik":"0001010823","reported_name":"Deerfield Mgmt L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":7,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":8,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":9,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29897,"kind":"person","name":"DEERFIELD PARTNERS, L.P.","position":10,"cik":"0001301041","reported_name":"DEERFIELD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2026-03-03T00:46:04.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":1084010,"price":5,"value":5420050.0,"ownership":{"direct":false,"nature":"Through Deerfield Private Design Fund III, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. (\"Deerfield Partners\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":10622928,"source":{"system":"sec-edgar","filing":"0001193805-26-000205","document":"e665206_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380526000205/e665206_4-larimar.xml","form_type":"4"}},{"id":873676,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":31399,"kind":"person","name":"Hamilton Thomas Edward","position":1,"cik":"0001769848","reported_name":"Hamilton Thomas Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-02T21:30:41.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":5,"value":500000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on February 27, 2026."}],"balance_after":664798,"source":{"system":"sec-edgar","filing":"0001193125-26-085515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526085515/ownership.xml","form_type":"4"}},{"id":873805,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-02T21:30:36.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5,"value":25000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on February 27, 2026."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001193125-26-085514","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000119312526085514/ownership.xml","form_type":"4"}},{"id":873730,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-02T21:30:19.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5,"value":25000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on February 27, 2026."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001193125-26-085510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000119312526085510/ownership.xml","form_type":"4"}},{"id":929845,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68692,"kind":"person","name":"Shankar Gopi","position":1,"cik":"0001965014","reported_name":"Shankar Gopi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-27T22:04:42.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":153822,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":153822,"derivative":{"exercise_price":3.6,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":153822},"source":{"system":"sec-edgar","filing":"0001193125-26-024833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526024833/ownership.xml","form_type":"4"}},{"id":929844,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68692,"kind":"person","name":"Shankar Gopi","position":1,"cik":"0001965014","reported_name":"Shankar Gopi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-01-27T22:04:42.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":25637,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":76443,"source":{"system":"sec-edgar","filing":"0001193125-26-024833","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526024833/ownership.xml","form_type":"4"}},{"id":929843,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68691,"kind":"person","name":"Clayton Russell","position":1,"cik":"0001530072","reported_name":"Clayton Russell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-27T22:04:28.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":153822,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":153822,"derivative":{"exercise_price":3.6,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":153822},"source":{"system":"sec-edgar","filing":"0001193125-26-024832","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526024832/ownership.xml","form_type":"4"}},{"id":929842,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68691,"kind":"person","name":"Clayton Russell","position":1,"cik":"0001530072","reported_name":"Clayton Russell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-27T22:04:28.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":25637,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":71443,"source":{"system":"sec-edgar","filing":"0001193125-26-024832","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526024832/ownership.xml","form_type":"4"}},{"id":929841,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68690,"kind":"person","name":"BEN-MAIMON CAROLE","position":1,"cik":"0001529611","reported_name":"BEN-MAIMON CAROLE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-27T22:04:08.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":600600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":600600,"derivative":{"exercise_price":3.6,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":600600},"source":{"system":"sec-edgar","filing":"0001193125-26-024826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526024826/ownership.xml","form_type":"4"}},{"id":929840,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68690,"kind":"person","name":"BEN-MAIMON CAROLE","position":1,"cik":"0001529611","reported_name":"BEN-MAIMON CAROLE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-27T22:04:08.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":100100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":368276,"source":{"system":"sec-edgar","filing":"0001193125-26-024826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526024826/ownership.xml","form_type":"4"}},{"id":929902,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68702,"kind":"person","name":"Celano Michael","position":1,"cik":"0001377582","reported_name":"Celano Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-27T17:03:39.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":225622,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":225622,"derivative":{"exercise_price":3.6,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":225622},"source":{"system":"sec-edgar","filing":"0001193125-26-024824","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377582/000119312526024824/ownership.xml","form_type":"4"}},{"id":929901,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68702,"kind":"person","name":"Celano Michael","position":1,"cik":"0001377582","reported_name":"Celano Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-27T17:03:39.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":37604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":215785,"source":{"system":"sec-edgar","filing":"0001193125-26-024824","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377582/000119312526024824/ownership.xml","form_type":"4"}},{"id":1076729,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29898,"kind":"person","name":"Deerfield Mgmt L.P.","position":6,"cik":"0001010823","reported_name":"Deerfield Mgmt L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":7,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":8,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":9,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29897,"kind":"person","name":"DEERFIELD PARTNERS, L.P.","position":10,"cik":"0001301041","reported_name":"DEERFIELD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2025-08-04T22:28:33.000Z","date":"2025-07-31","kind":"purchase","planned":false,"acquired":true,"shares":2599932,"price":3.2,"value":8319782.4,"ownership":{"direct":false,"nature":"Through Deerfield Healthcare Innovations Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. (\"Deerfield Partners\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":7321129,"source":{"system":"sec-edgar","filing":"0001193805-25-001155","document":"e664762_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380525001155/e664762_4-larimar.xml","form_type":"4"}},{"id":1076728,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29898,"kind":"person","name":"Deerfield Mgmt L.P.","position":6,"cik":"0001010823","reported_name":"Deerfield Mgmt L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":7,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":8,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":9,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29897,"kind":"person","name":"DEERFIELD PARTNERS, L.P.","position":10,"cik":"0001301041","reported_name":"DEERFIELD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2025-08-04T22:28:33.000Z","date":"2025-07-31","kind":"purchase","planned":false,"acquired":true,"shares":3387539,"price":3.2,"value":10840124.8,"ownership":{"direct":false,"nature":"Through Deerfield Private Design Fund IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. (\"Deerfield Partners\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":9538945,"source":{"system":"sec-edgar","filing":"0001193805-25-001155","document":"e664762_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380525001155/e664762_4-larimar.xml","form_type":"4"}},{"id":1076727,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29898,"kind":"person","name":"Deerfield Mgmt L.P.","position":6,"cik":"0001010823","reported_name":"Deerfield Mgmt L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":7,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":8,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":9,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29897,"kind":"person","name":"DEERFIELD PARTNERS, L.P.","position":10,"cik":"0001301041","reported_name":"DEERFIELD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2025-08-04T22:28:33.000Z","date":"2025-07-31","kind":"purchase","planned":false,"acquired":true,"shares":3387529,"price":3.2,"value":10840092.8,"ownership":{"direct":false,"nature":"Through Deerfield Private Design Fund III, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. (\"Deerfield Partners\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":9538918,"source":{"system":"sec-edgar","filing":"0001193805-25-001155","document":"e664762_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380525001155/e664762_4-larimar.xml","form_type":"4"}},{"id":1148053,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-15T23:44:19.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Through Deerfield Management Company, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on May 13, 2025 and is scheduled to vest on the earlier of May 13, 2026 and the date of the Issuer's next annual meeting of stockholders, in each case, subject to Jonathan S. Leff 's continued service on the board of directors of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). James E. Flynn is the sole member of the general partner of Deerfield Management Company, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":19000,"derivative":{"exercise_price":1.875,"expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001193805-25-000672","document":"e664519_4-larimar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380525000672/e664519_4-larimar.xml","form_type":"4"}},{"id":1148955,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-14T20:34:08.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 13, 2026 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":1.875,"expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-25-009380","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000106299325009380/form4.xml","form_type":"4"}},{"id":1149125,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-14T20:33:51.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 13, 2026 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":1.875,"expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-25-009379","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000106299325009379/form4.xml","form_type":"4"}},{"id":1148913,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":31399,"kind":"person","name":"Hamilton Thomas Edward","position":1,"cik":"0001769848","reported_name":"Hamilton Thomas Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-14T20:33:13.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 13, 2026 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":1.875,"expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-25-009378","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299325009378/form4.xml","form_type":"4"}},{"id":1148998,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-14T20:32:51.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 13, 2026 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":1.875,"expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-25-009377","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000106299325009377/form4.xml","form_type":"4"}},{"id":1148956,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45622,"kind":"person","name":"LEFF JONATHAN S","position":1,"cik":"0001215242","reported_name":"LEFF JONATHAN S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-14T20:32:22.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest on the earlier of (a) May 13, 2026 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."}],"balance_after":19000,"derivative":{"exercise_price":1.875,"expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-25-009376","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1215242/000106299325009376/form4.xml","form_type":"4"}},{"id":1295387,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68692,"kind":"person","name":"Shankar Gopi","position":1,"cik":"0001965014","reported_name":"Shankar Gopi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-24T21:16:59.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":139838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on January 22, 2026, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":139838,"derivative":{"exercise_price":3.46,"expiration_date":"2035-01-22","underlying":"Common Stock","underlying_shares":139838},"source":{"system":"sec-edgar","filing":"0001062993-25-001080","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299325001080/form4.xml","form_type":"4"}},{"id":1295386,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68692,"kind":"person","name":"Shankar Gopi","position":1,"cik":"0001965014","reported_name":"Shankar Gopi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-01-24T21:16:59.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":23306,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":50806,"source":{"system":"sec-edgar","filing":"0001062993-25-001080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299325001080/form4.xml","form_type":"4"}},{"id":1295385,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68691,"kind":"person","name":"Clayton Russell","position":1,"cik":"0001530072","reported_name":"Clayton Russell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-24T21:16:21.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":139838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on January 22, 2026, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":139838,"derivative":{"exercise_price":3.46,"expiration_date":"2035-01-22","underlying":"Common Stock","underlying_shares":139838},"source":{"system":"sec-edgar","filing":"0001062993-25-001079","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299325001079/form4.xml","form_type":"4"}},{"id":1295384,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68691,"kind":"person","name":"Clayton Russell","position":1,"cik":"0001530072","reported_name":"Clayton Russell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-24T21:16:21.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":23306,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":45806,"source":{"system":"sec-edgar","filing":"0001062993-25-001079","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299325001079/form4.xml","form_type":"4"}},{"id":1295383,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68690,"kind":"person","name":"BEN-MAIMON CAROLE","position":1,"cik":"0001529611","reported_name":"BEN-MAIMON CAROLE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-24T21:15:42.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":546000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests 25% on January 22, 2026, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":546000,"derivative":{"exercise_price":3.46,"expiration_date":"2035-01-22","underlying":"Common Stock","underlying_shares":546000},"source":{"system":"sec-edgar","filing":"0001062993-25-001078","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299325001078/form4.xml","form_type":"4"}},{"id":1295382,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68690,"kind":"person","name":"BEN-MAIMON CAROLE","position":1,"cik":"0001529611","reported_name":"BEN-MAIMON CAROLE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-24T21:15:42.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":91000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":387208,"source":{"system":"sec-edgar","filing":"0001062993-25-001078","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299325001078/form4.xml","form_type":"4"}},{"id":1295493,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68702,"kind":"person","name":"Celano Michael","position":1,"cik":"0001377582","reported_name":"Celano Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-24T16:15:00.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":205111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on January 22, 2026, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":205111,"derivative":{"exercise_price":3.46,"expiration_date":"2035-01-22","underlying":"Common Stock","underlying_shares":205111},"source":{"system":"sec-edgar","filing":"0001062993-25-001077","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377582/000106299325001077/form4.xml","form_type":"4"}},{"id":1295492,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68702,"kind":"person","name":"Celano Michael","position":1,"cik":"0001377582","reported_name":"Celano Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-24T16:15:00.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":34185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":178181,"source":{"system":"sec-edgar","filing":"0001062993-25-001077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377582/000106299325001077/form4.xml","form_type":"4"}},{"id":1495690,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-03T22:31:14.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Through Deerfield Management Company, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on May 29, 2024 and is scheduled to vest on the earlier of May 29, 2025 and the date of the Issuer's next annual meeting of stockholders, in each case, subject to Jonathan S. Leff 's continued service on the board of directors of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). James E. Flynn is the sole member of the general partner of Deerfield Management Company, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":19000,"derivative":{"exercise_price":7.07,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001193805-24-000743","document":"e663682_4-larimar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380524000743/e663682_4-larimar.xml","form_type":"4"}},{"id":1496445,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T20:58:04.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 29, 2025 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":7.07,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-24-011572","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000106299324011572/form4.xml","form_type":"4"}},{"id":1496420,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45622,"kind":"person","name":"LEFF JONATHAN S","position":1,"cik":"0001215242","reported_name":"LEFF JONATHAN S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T20:57:54.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest on the earlier of (a) May 29, 2025 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."}],"balance_after":19000,"derivative":{"exercise_price":7.07,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-24-011571","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1215242/000106299324011571/form4.xml","form_type":"4"}},{"id":1496415,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T20:57:35.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 29, 2025 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":7.07,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-24-011570","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000106299324011570/form4.xml","form_type":"4"}},{"id":1496629,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T20:57:17.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 29, 2025 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":7.07,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-24-011569","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000106299324011569/form4.xml","form_type":"4"}},{"id":1496375,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":31399,"kind":"person","name":"Hamilton Thomas Edward","position":1,"cik":"0001769848","reported_name":"Hamilton Thomas Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T20:56:58.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest on the earlier of (a) May 29, 2025 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":7.07,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-24-011568","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299324011568/form4.xml","form_type":"4"}},{"id":1496374,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":31399,"kind":"person","name":"Hamilton Thomas Edward","position":1,"cik":"0001769848","reported_name":"Hamilton Thomas Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T20:56:58.000Z","date":"2024-02-16","kind":"purchase","planned":false,"acquired":true,"shares":57208,"price":8.74,"value":499997.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. (the \"Company\") at the offering price, which closed on February 16, 2024."}],"balance_after":564798,"source":{"system":"sec-edgar","filing":"0001062993-24-011568","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299324011568/form4.xml","form_type":"4"}},{"id":1639318,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29898,"kind":"person","name":"Deerfield Mgmt L.P.","position":6,"cik":"0001010823","reported_name":"Deerfield Mgmt L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":7,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":8,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":9,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29897,"kind":"person","name":"DEERFIELD PARTNERS, L.P.","position":10,"cik":"0001301041","reported_name":"DEERFIELD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2024-02-16T19:37:50.000Z","date":"2024-02-16","kind":"purchase","planned":false,"acquired":true,"shares":1430205,"price":8.74,"value":12499991.7,"ownership":{"direct":false,"nature":"Through Deerfield Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. (\"Deerfield Partners\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4207982,"source":{"system":"sec-edgar","filing":"0001193805-24-000245","document":"e619284_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380524000245/e619284_4-larimar.xml","form_type":"4"}},{"id":1639317,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29898,"kind":"person","name":"Deerfield Mgmt L.P.","position":6,"cik":"0001010823","reported_name":"Deerfield Mgmt L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":7,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":8,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":9,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29897,"kind":"person","name":"DEERFIELD PARTNERS, L.P.","position":10,"cik":"0001301041","reported_name":"DEERFIELD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2024-02-16T19:37:50.000Z","date":"2024-02-16","kind":"purchase","planned":false,"acquired":true,"shares":1430206,"price":8.74,"value":12500000.44,"ownership":{"direct":false,"nature":"Through Deerfield Private Design Fund IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. (\"Deerfield Partners\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":6151406,"source":{"system":"sec-edgar","filing":"0001193805-24-000245","document":"e619284_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380524000245/e619284_4-larimar.xml","form_type":"4"}},{"id":1639316,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29898,"kind":"person","name":"Deerfield Mgmt L.P.","position":6,"cik":"0001010823","reported_name":"Deerfield Mgmt L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":7,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":8,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":9,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29897,"kind":"person","name":"DEERFIELD PARTNERS, L.P.","position":10,"cik":"0001301041","reported_name":"DEERFIELD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2024-02-16T19:37:50.000Z","date":"2024-02-16","kind":"purchase","planned":false,"acquired":true,"shares":1430206,"price":8.74,"value":12500000.44,"ownership":{"direct":false,"nature":"Through Deerfield Private Design Fund III, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. (\"Deerfield Partners\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":6151389,"source":{"system":"sec-edgar","filing":"0001193805-24-000245","document":"e619284_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380524000245/e619284_4-larimar.xml","form_type":"4"}},{"id":1640756,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T21:21:16.000Z","date":"2024-02-14","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":11,"value":22000.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001062993-24-003312","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000106299324003312/form4.xml","form_type":"4"}},{"id":1675014,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68692,"kind":"person","name":"Shankar Gopi","position":1,"cik":"0001965014","reported_name":"Shankar Gopi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-19T21:33:33.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":135000,"derivative":{"exercise_price":4.21,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001062993-24-001086","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299324001086/form4.xml","form_type":"4"}},{"id":1675013,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68692,"kind":"person","name":"Shankar Gopi","position":1,"cik":"0001965014","reported_name":"Shankar Gopi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-01-19T21:33:33.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":27500,"source":{"system":"sec-edgar","filing":"0001062993-24-001086","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299324001086/form4.xml","form_type":"4"}},{"id":1675012,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68691,"kind":"person","name":"Clayton Russell","position":1,"cik":"0001530072","reported_name":"Clayton Russell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-19T21:31:40.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":135000,"derivative":{"exercise_price":4.21,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001062993-24-001084","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299324001084/form4.xml","form_type":"4"}},{"id":1675011,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68691,"kind":"person","name":"Clayton Russell","position":1,"cik":"0001530072","reported_name":"Clayton Russell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-19T21:31:40.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":22500,"source":{"system":"sec-edgar","filing":"0001062993-24-001084","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299324001084/form4.xml","form_type":"4"}},{"id":1675010,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68690,"kind":"person","name":"BEN-MAIMON CAROLE","position":1,"cik":"0001529611","reported_name":"BEN-MAIMON CAROLE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-19T21:31:11.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":396750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":396750,"derivative":{"exercise_price":4.21,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":396750},"source":{"system":"sec-edgar","filing":"0001062993-24-001083","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299324001083/form4.xml","form_type":"4"}},{"id":1675009,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68690,"kind":"person","name":"BEN-MAIMON CAROLE","position":1,"cik":"0001529611","reported_name":"BEN-MAIMON CAROLE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-19T21:31:11.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":66125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":332954,"source":{"system":"sec-edgar","filing":"0001062993-24-001083","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299324001083/form4.xml","form_type":"4"}},{"id":1675101,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68702,"kind":"person","name":"Celano Michael","position":1,"cik":"0001377582","reported_name":"Celano Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-19T16:32:58.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":187500,"derivative":{"exercise_price":4.21,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0001062993-24-001085","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377582/000106299324001085/form4.xml","form_type":"4"}},{"id":1675100,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68702,"kind":"person","name":"Celano Michael","position":1,"cik":"0001377582","reported_name":"Celano Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-19T16:32:58.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":143996,"source":{"system":"sec-edgar","filing":"0001062993-24-001085","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377582/000106299324001085/form4.xml","form_type":"4"}},{"id":1717570,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68692,"kind":"person","name":"Shankar Gopi","position":1,"cik":"0001965014","reported_name":"Shankar Gopi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-12-08T21:08:38.000Z","date":"2023-12-07","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":3.7323,"value":18661.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.73 to $3.768, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001062993-23-022200","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299323022200/form4.xml","form_type":"4"}},{"id":1764276,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-05T20:33:01.000Z","date":"2023-10-03","kind":"grant","planned":false,"acquired":true,"shares":16600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments over 36 months commencing on November 3, 2023, subject to the Reporting Person's continued service on the Board of Directors of the Company through each applicable vesting date."}],"balance_after":16600,"derivative":{"exercise_price":3.555,"expiration_date":"2033-10-03","underlying":"Common Stock","underlying_shares":16600},"source":{"system":"sec-edgar","filing":"0001062993-23-019067","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000106299323019067/form4.xml","form_type":"4"}},{"id":1827671,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68691,"kind":"person","name":"Clayton Russell","position":1,"cik":"0001530072","reported_name":"Clayton Russell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-18T20:15:06.000Z","date":"2023-07-17","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests 25% on July 17, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":180000,"derivative":{"exercise_price":3.22,"expiration_date":"2033-07-17","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001062993-23-014993","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299323014993/form4.xml","form_type":"4"}},{"id":1886568,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68690,"kind":"person","name":"BEN-MAIMON CAROLE","position":1,"cik":"0001529611","reported_name":"BEN-MAIMON CAROLE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-05-18T18:13:12.000Z","date":"2023-05-17","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":3.705,"value":18525.0,"ownership":{"direct":true},"balance_after":266829,"source":{"system":"sec-edgar","filing":"0001062993-23-011546","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299323011546/form4.xml","form_type":"4"}},{"id":1886767,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-18T18:12:44.000Z","date":"2023-05-17","kind":"purchase","planned":false,"acquired":true,"shares":2750,"price":3.73,"value":10257.5,"ownership":{"direct":true},"balance_after":2750,"source":{"system":"sec-edgar","filing":"0001062993-23-011545","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000106299323011545/form4.xml","form_type":"4"}},{"id":1886707,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68702,"kind":"person","name":"Celano Michael","position":1,"cik":"0001377582","reported_name":"Celano Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-18T14:13:33.000Z","date":"2023-05-17","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":3.7263,"value":18631.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.71 to $3.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":112746,"source":{"system":"sec-edgar","filing":"0001062993-23-011547","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377582/000106299323011547/form4.xml","form_type":"4"}},{"id":1897198,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-11T22:31:30.000Z","date":"2023-05-09","kind":"grant","planned":false,"acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Through Deerfield Management Company, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on May 9, 2023 and is scheduled to vest on the earlier of May 9, 2024 and the date of the Issuer's next annual meeting of stockholders, in each case, subject to Jonathan S. Leff 's continued service on the board of directors of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). James E. Flynn is the sole member of the general partner of Deerfield Management Company, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":8300,"derivative":{"exercise_price":5.09,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001193805-23-000711","document":"e618621_4-larimar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380523000711/e618621_4-larimar.xml","form_type":"4"}},{"id":1896666,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-11T20:29:49.000Z","date":"2023-05-09","kind":"grant","planned":false,"acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":5.09,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-23-010808","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000106299323010808/form4.xml","form_type":"4"}},{"id":1896473,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":31399,"kind":"person","name":"Hamilton Thomas Edward","position":1,"cik":"0001769848","reported_name":"Hamilton Thomas Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-11T20:29:31.000Z","date":"2023-05-09","kind":"grant","planned":false,"acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":5.09,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-23-010807","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299323010807/form4.xml","form_type":"4"}},{"id":1896519,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45622,"kind":"person","name":"LEFF JONATHAN S","position":1,"cik":"0001215242","reported_name":"LEFF JONATHAN S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-11T20:29:14.000Z","date":"2023-05-09","kind":"grant","planned":false,"acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."}],"balance_after":8300,"derivative":{"exercise_price":5.09,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-23-010806","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1215242/000106299323010806/form4.xml","form_type":"4"}},{"id":1896567,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-11T20:28:50.000Z","date":"2023-05-09","kind":"grant","planned":false,"acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":5.09,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-23-010805","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000106299323010805/form4.xml","form_type":"4"}},{"id":2024415,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68692,"kind":"person","name":"Shankar Gopi","position":1,"cik":"0001965014","reported_name":"Shankar Gopi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-09T22:06:58.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests 25% on February 7, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":180000,"derivative":{"exercise_price":5.88,"expiration_date":"2033-02-07","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0000899243-23-004438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000089924323004438/doc4.xml","form_type":"4"}},{"id":2035355,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68690,"kind":"person","name":"BEN-MAIMON CAROLE","position":1,"cik":"0001529611","reported_name":"BEN-MAIMON CAROLE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T01:15:26.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on January 31, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":325000,"derivative":{"exercise_price":4.94,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0000899243-23-003734","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000089924323003734/doc4.xml","form_type":"4"}},{"id":2035354,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68690,"kind":"person","name":"BEN-MAIMON CAROLE","position":1,"cik":"0001529611","reported_name":"BEN-MAIMON CAROLE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-03T01:15:26.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":205000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":261829,"source":{"system":"sec-edgar","filing":"0000899243-23-003734","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000089924323003734/doc4.xml","form_type":"4"}},{"id":2035739,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68702,"kind":"person","name":"Celano Michael","position":1,"cik":"0001377582","reported_name":"Celano Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-02T20:16:57.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on January 31, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":120000,"derivative":{"exercise_price":4.94,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000899243-23-003735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377582/000089924323003735/doc4.xml","form_type":"4"}},{"id":2035738,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68702,"kind":"person","name":"Celano Michael","position":1,"cik":"0001377582","reported_name":"Celano Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-02T20:16:57.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":76000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":107746,"source":{"system":"sec-edgar","filing":"0000899243-23-003735","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377582/000089924323003735/doc4.xml","form_type":"4"}},{"id":2154360,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":6,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":7,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":8,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2022-09-21T00:31:45.000Z","date":"2022-09-16","kind":"purchase","acquired":true,"shares":2777777,"price":3.15,"value":8749997.55,"ownership":{"direct":false,"nature":"Through Deerfield Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":2777777,"source":{"system":"sec-edgar","filing":"0001193805-22-001296","document":"e621937_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380522001296/e621937_4-larimar.xml","form_type":"4"}},{"id":2154359,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":6,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":7,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":8,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2022-09-21T00:31:45.000Z","date":"2022-09-16","kind":"purchase","acquired":true,"shares":2777777,"price":3.15,"value":8749997.55,"ownership":{"direct":false,"nature":"Through Deerfield Healthcare Innovations Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4721197,"source":{"system":"sec-edgar","filing":"0001193805-22-001296","document":"e621937_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380522001296/e621937_4-larimar.xml","form_type":"4"}},{"id":2154358,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":6,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":7,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":8,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2022-09-21T00:31:45.000Z","date":"2022-09-16","kind":"purchase","acquired":true,"shares":2777777,"price":3.15,"value":8749997.55,"ownership":{"direct":false,"nature":"Through Deerfield Private Design Fund IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4721200,"source":{"system":"sec-edgar","filing":"0001193805-22-001296","document":"e621937_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380522001296/e621937_4-larimar.xml","form_type":"4"}},{"id":2154357,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":6,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":7,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":8,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2022-09-21T00:31:45.000Z","date":"2022-09-16","kind":"purchase","acquired":true,"shares":2777777,"price":3.15,"value":8749997.55,"ownership":{"direct":false,"nature":"Through Deerfield Private Design Fund III, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (\"Fund IV\"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the \"Funds\"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4721183,"source":{"system":"sec-edgar","filing":"0001193805-22-001296","document":"e621937_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380522001296/e621937_4-larimar.xml","form_type":"4"}},{"id":2153908,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":31399,"kind":"person","name":"Hamilton Thomas Edward","position":1,"cik":"0001769848","reported_name":"Hamilton Thomas Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T10:54:26.000Z","date":"2022-09-16","kind":"purchase","acquired":true,"shares":317460,"price":3.15,"value":999999.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on September 16, 2022."}],"balance_after":507590,"source":{"system":"sec-edgar","filing":"0001062993-22-019753","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299322019753/form4.xml","form_type":"4"}},{"id":2155350,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68690,"kind":"person","name":"BEN-MAIMON CAROLE","position":1,"cik":"0001529611","reported_name":"BEN-MAIMON CAROLE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-19T11:00:11.000Z","date":"2022-09-16","kind":"purchase","acquired":true,"shares":31746,"price":3.15,"value":99999.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on September 16, 2022."}],"balance_after":56829,"source":{"system":"sec-edgar","filing":"0001062993-22-019645","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299322019645/form4.xml","form_type":"4"}},{"id":2155680,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68702,"kind":"person","name":"Celano Michael","position":1,"cik":"0001377582","reported_name":"Celano Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-09-19T07:00:34.000Z","date":"2022-09-16","kind":"purchase","acquired":true,"shares":31746,"price":3.15,"value":99999.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on September 16, 2022."}],"balance_after":31746,"source":{"system":"sec-edgar","filing":"0001062993-22-019646","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377582/000106299322019646/form4.xml","form_type":"4"}},{"id":2273186,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68690,"kind":"person","name":"BEN-MAIMON CAROLE","position":1,"cik":"0001529611","reported_name":"BEN-MAIMON CAROLE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-13T00:28:44.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests 25% on May 10, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates."}],"balance_after":40000,"derivative":{"exercise_price":2.92,"expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001062993-22-012309","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299322012309/form4.xml","form_type":"4"}},{"id":2273458,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-13T00:28:04.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":2.92,"expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-22-012307","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000106299322012307/form4.xml","form_type":"4"}},{"id":2273326,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":26196,"kind":"person","name":"Barrett Peter","position":1,"cik":"0001291895","reported_name":"Barrett Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-13T00:27:47.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":2.92,"expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-22-012306","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291895/000106299322012306/form4.xml","form_type":"4"}},{"id":2273184,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":31399,"kind":"person","name":"Hamilton Thomas Edward","position":1,"cik":"0001769848","reported_name":"Hamilton Thomas Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-13T00:27:31.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":2.92,"expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-22-012305","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299322012305/form4.xml","form_type":"4"}},{"id":2273253,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45622,"kind":"person","name":"LEFF JONATHAN S","position":1,"cik":"0001215242","reported_name":"LEFF JONATHAN S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-13T00:27:18.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P."}],"balance_after":8300,"derivative":{"exercise_price":2.92,"expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-22-012304","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1215242/000106299322012304/form4.xml","form_type":"4"}},{"id":2273296,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-13T00:26:59.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":2.92,"expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-22-012303","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000106299322012303/form4.xml","form_type":"4"}},{"id":2273348,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68702,"kind":"person","name":"Celano Michael","position":1,"cik":"0001377582","reported_name":"Celano Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-12T20:28:24.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests 25% on May 10, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates."}],"balance_after":20000,"derivative":{"exercise_price":2.92,"expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001062993-22-012308","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377582/000106299322012308/form4.xml","form_type":"4"}},{"id":2275210,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-11T21:42:24.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Through Deerfield Management Company, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on May 10, 2022 and is scheduled to vest on the earlier of May 10, 2023 and the date of the Issuer's next annual meeting of stockholders, in each case, subject to Jonathan S. Leff 's continued service on the board of directors of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). James E. Flynn is the sole member of the general partner of Deerfield Management Company, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":8300,"derivative":{"exercise_price":2.92,"expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001193805-22-000771","document":"e621645_4-larimar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380522000771/e621645_4-larimar.xml","form_type":"4"}},{"id":2429950,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68690,"kind":"person","name":"BEN-MAIMON CAROLE","position":1,"cik":"0001529611","reported_name":"BEN-MAIMON CAROLE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-21T00:16:23.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":182000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests 25% on January 18, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":182000,"derivative":{"exercise_price":8.75,"expiration_date":"2032-01-18","underlying":"Common Stock","underlying_shares":182000},"source":{"system":"sec-edgar","filing":"0001062993-22-001319","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000106299322001319/form4.xml","form_type":"4"}},{"id":2430258,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":68702,"kind":"person","name":"Celano Michael","position":1,"cik":"0001377582","reported_name":"Celano Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-20T19:19:06.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests 25% on January 18, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date."}],"balance_after":80000,"derivative":{"exercise_price":8.75,"expiration_date":"2032-01-18","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001062993-22-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377582/000106299322001320/form4.xml","form_type":"4"}},{"id":2645846,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":6,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":7,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":8,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2021-07-02T21:07:18.000Z","date":"2021-06-30","kind":"purchase","acquired":true,"shares":228570,"price":8.75,"value":1999987.5,"ownership":{"direct":false,"nature":"Through Deerfield Healthcare Innovations Fund, L.P."},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The shares reported herein as being held through Deerfield Private Design Fund III, L.P. (\"Fund III\"), Deerfield Private Design Fund IV, L.P. (\"Fund IV\") and Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\" and, collectively with Fund III and Fund IV, the \"Funds\") include shares that were previously reported as being held indirectly through Chondrial Therapeutics Holdings, LLC (\"Chondrial\"), which shares were distributed to the Funds pursuant to a pro rata distribution to the members of Chondrial."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Fund III. Deerfield Mgmt IV, L.P. is the general partner of Fund IV. Deerfield Mgmt HIF, L.P. is the general partner of Deerfield HIF. Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":1943420,"source":{"system":"sec-edgar","filing":"0001193805-21-000974","document":"e620772_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380521000974/e620772_4-larimar.xml","form_type":"4"}},{"id":2645845,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":6,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":7,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":8,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2021-07-02T21:07:18.000Z","date":"2021-06-30","kind":"purchase","acquired":true,"shares":228571,"price":8.75,"value":1999996.25,"ownership":{"direct":false,"nature":"Through Deerfield Private Design Fund IV, L.P."},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The shares reported herein as being held through Deerfield Private Design Fund III, L.P. (\"Fund III\"), Deerfield Private Design Fund IV, L.P. (\"Fund IV\") and Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\" and, collectively with Fund III and Fund IV, the \"Funds\") include shares that were previously reported as being held indirectly through Chondrial Therapeutics Holdings, LLC (\"Chondrial\"), which shares were distributed to the Funds pursuant to a pro rata distribution to the members of Chondrial."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Fund III. Deerfield Mgmt IV, L.P. is the general partner of Fund IV. Deerfield Mgmt HIF, L.P. is the general partner of Deerfield HIF. Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":1943423,"source":{"system":"sec-edgar","filing":"0001193805-21-000974","document":"e620772_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380521000974/e620772_4-larimar.xml","form_type":"4"}},{"id":2645844,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29895,"kind":"person","name":"Deerfield Mgmt HIF, L.P.","position":4,"cik":"0001665736","reported_name":"Deerfield Mgmt HIF, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":6,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29896,"kind":"person","name":"Deerfield Healthcare Innovations Fund, L.P.","position":7,"cik":"0001646981","reported_name":"Deerfield Healthcare Innovations Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":8,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Common Stock","published_at":"2021-07-02T21:07:18.000Z","date":"2021-06-30","kind":"purchase","acquired":true,"shares":228569,"price":8.75,"value":1999978.75,"ownership":{"direct":false,"nature":"Through Deerfield Private Design Fund III, L.P."},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The shares reported herein as being held through Deerfield Private Design Fund III, L.P. (\"Fund III\"), Deerfield Private Design Fund IV, L.P. (\"Fund IV\") and Deerfield Healthcare Innovations Fund, L.P. (\"Deerfield HIF\" and, collectively with Fund III and Fund IV, the \"Funds\") include shares that were previously reported as being held indirectly through Chondrial Therapeutics Holdings, LLC (\"Chondrial\"), which shares were distributed to the Funds pursuant to a pro rata distribution to the members of Chondrial."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Fund III. Deerfield Mgmt IV, L.P. is the general partner of Fund IV. Deerfield Mgmt HIF, L.P. is the general partner of Deerfield HIF. Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":1943406,"source":{"system":"sec-edgar","filing":"0001193805-21-000974","document":"e620772_4-larimar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380521000974/e620772_4-larimar.xml","form_type":"4"}},{"id":2643846,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":31399,"kind":"person","name":"Hamilton Thomas Edward","position":1,"cik":"0001769848","reported_name":"Hamilton Thomas Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T20:08:42.000Z","date":"2021-06-30","kind":"purchase","acquired":true,"shares":56710,"price":8.75,"value":496212.5,"ownership":{"direct":true},"balance_after":190130,"source":{"system":"sec-edgar","filing":"0001192482-21-000601","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000119248221000601/edgar.xml","form_type":"4"}},{"id":2703032,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-20T12:48:38.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option vests on the earlier of (a) May 12, 2022 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":10.34,"expiration_date":"2031-05-12","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001192482-21-000445","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000119248221000445/edgar.xml","form_type":"4"}},{"id":2711022,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"* Director by Deputization"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-17T21:17:02.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Through Deerfield Management Company, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on May 12, 2021 and is scheduled to vest on the earlier of May 12, 2022 and the date of the Issuer's next annual meeting of stockholders, in each case, subject to Jonathan S. Leff 's continued service with the Issuer through each applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. (\"Deerfield Management\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). James E. Flynn is the sole member of the general partner of Deerfield Management Company, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":8300,"derivative":{"exercise_price":10.34,"expiration_date":"2031-05-12","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001193805-21-000685","document":"e620613_4-larimar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380521000685/e620613_4-larimar.xml","form_type":"4"}},{"id":2710066,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45622,"kind":"person","name":"LEFF JONATHAN S","position":1,"cik":"0001215242","reported_name":"LEFF JONATHAN S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-17T21:09:51.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the option for the benefit, and at the direction, of Deerfield Management Company, L.P."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option vests on the earlier of (a) May 12, 2022 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the option for the benefit, and at the direction, of Deerfield Management Company, L.P."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the option for the benefit, and at the direction, of Deerfield Management Company, L.P."}],"balance_after":8300,"derivative":{"exercise_price":10.34,"expiration_date":"2031-05-12","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001192482-21-000442","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1215242/000119248221000442/edgar.xml","form_type":"4"}}],"next_cursor":"2021-05-17T21:09:51.000000Z,2710066"}